Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling

• DOI: 10.1007/s00381-021-05278-6
• Publication Date: 2021-07-26T08:02:52Z
• Authors: Catena Kresbach; Annika Bronsema; Helena Guerreiro; Stefan Rutkowski; Ulrich Schüller; Beate Winkler
• Keywords: Valproic Acid; Temozolomide; Dacarbazine; Brain tumor

Abstract Glioblastoma (GBM) is an exceptionally aggressive brain tumor with a dismal prognosis, demanding fast and precise classification as base for patient-specific treatment strategies. Here, we report on adolescent patient histologically bona fide GBM that shows molecular methylation profile suggesting low-grade glioma-like subgroup. Despite early relapse, intolerance of temozolomide, change strategy to vinblastine valproic acid (VPA), the now in good clinical condition after more than 5 years since initial diagnosis. This case stresses merit array data prognosis planning.